- BieGene to receive $650M as up front along with milestones and royalties and will retain rights to Tislelizumab in China and other countries
- Novartis to get the development & commercialization rights to tislelizumab in the US, Canada, Mexico, EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia, & Japan. Additionally, the companies have identified multiple tislelizumab + Novartis’ therapy combination clinical trial opportunities in solid tumors
- Tislelizumab is an anti-PD-1 mAb, designed to minimize binding to FcγR on macrophages and is approved in China for patients with cHL and m-UC in China while 15 registration-enabling clinical trials under way in NSCLC and other solid tumors
Click here to read full press release/ article | Ref: Novartis | Image: Outsourcing Pharma
The post Novartis In-Licenses BieGene’s Tislelizumab to Expand its Oncology Portfolio first appeared on PharmaShots.